See more : Ningxia Zhongyin Cashmere Co., Ltd. (000982.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Avantor, Inc. (AVTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avantor, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Ngai Hing Hong Company Limited (1047.HK) Income Statement Analysis – Financial Results
- Aartech Solonics Limited (AARTECH.BO) Income Statement Analysis – Financial Results
- Linde plc (LIN.SW) Income Statement Analysis – Financial Results
- Cellectis S.A. (ALCLS.PA) Income Statement Analysis – Financial Results
- Kuo Yang Construction Co.,Ltd (2505.TW) Income Statement Analysis – Financial Results
Avantor, Inc. (AVTR)
About Avantor, Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.97B | 7.51B | 7.39B | 6.39B | 6.04B | 5.86B | 1.25B | 691.30M | 636.90M | 4.91B |
| Cost of Revenue | 4.60B | 4.91B | 4.88B | 4.31B | 4.12B | 4.04B | 814.60M | 371.60M | 374.70M | 2.31B |
| Gross Profit | 2.36B | 2.60B | 2.50B | 2.08B | 1.92B | 1.82B | 432.80M | 319.70M | 262.20M | 2.60B |
| Gross Profit Ratio | 33.93% | 34.65% | 33.88% | 32.54% | 31.80% | 31.03% | 34.70% | 46.25% | 41.17% | 53.01% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.10M | 21.90M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.60M | 1.47B |
| Other Expenses | 0.00 | -800.00K | 10.60M | 9.90M | 2.50M | 3.00M | 3.40M | 200.00K | -300.00K | 0.00 |
| Operating Expenses | 1.66B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.90M | 1.47B |
| Cost & Expenses | 6.26B | 6.38B | 6.41B | 5.69B | 5.49B | 5.45B | 1.46B | 681.40M | 576.60M | 3.78B |
| Interest Income | 0.00 | 265.80M | 229.30M | 307.60M | 440.00M | 0.00 | 0.00 | 0.00 | 30.60M | 0.00 |
| Interest Expense | 284.80M | 265.80M | 217.40M | 307.60M | 440.00M | 523.80M | 200.90M | 80.30M | 0.00 | -265.80M |
| Depreciation & Amortization | 402.30M | 405.50M | 379.20M | 395.40M | 398.90M | 404.60M | 99.20M | 60.30M | 60.70M | 0.00 |
| EBITDA | 1.13B | 1.53B | 1.35B | 765.30M | 879.50M | 814.60M | -91.20M | 70.40M | 121.10M | 1.13B |
| EBITDA Ratio | 16.19% | 20.43% | 18.44% | 17.39% | 15.78% | 14.00% | -8.64% | 10.18% | 19.00% | 23.02% |
| Operating Income | 696.40M | 1.13B | 972.20M | 706.80M | 551.80M | 413.50M | -210.40M | 9.90M | 60.30M | 1.13B |
| Operating Income Ratio | 10.00% | 15.04% | 13.16% | 11.05% | 9.14% | 7.05% | -16.87% | 1.43% | 9.47% | 23.02% |
| Total Other Income/Expenses | -285.90M | -279.10M | -219.20M | -644.50M | -511.20M | -527.30M | -249.80M | -80.50M | -30.50M | -279.10M |
| Income Before Tax | 410.50M | 851.10M | 753.00M | 62.30M | 40.60M | -113.80M | -460.20M | -70.60M | 29.80M | 851.10M |
| Income Before Tax Ratio | 5.89% | 11.33% | 10.19% | 0.97% | 0.67% | -1.94% | -36.89% | -10.21% | 4.68% | 17.34% |
| Income Tax Expense | 89.40M | 164.60M | 180.40M | -54.30M | 2.80M | -26.90M | -314.90M | 10.10M | 17.10M | -164.60M |
| Net Income | 321.10M | 686.50M | 572.60M | 116.60M | 37.80M | -86.90M | -112.70M | -42.40M | 21.60M | 686.50M |
| Net Income Ratio | 4.61% | 9.14% | 7.75% | 1.82% | 0.63% | -1.48% | -9.03% | -6.13% | 3.39% | 13.98% |
| EPS | 0.48 | 1.02 | 0.86 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.05 |
| EPS Diluted | 0.47 | 1.01 | 0.85 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.01 |
| Weighted Avg Shares Out | 675.60M | 650.90M | 590.50M | 576.30M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 650.90M |
| Weighted Avg Shares Out (Dil) | 678.40M | 679.40M | 599.60M | 583.40M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 679.40M |
Avantor® Reports Third Quarter 2024 Results
Avantor® Strengthens Partnership with National Institute for Bioprocessing Research and Training (NIBRT) to Address Critical Biopharma Industry Challenges
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
Audax Private Equity Completes Carveout of Avantor, Inc.'s Clinical Services Business and Rebrands the Company as Resonant Clinical Solutions
Avantor® Closes Previously Announced Divestiture of its Clinical Services Business
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
Avantor® Wins Kaizen Institute Award for Excellence in Process Improvement and Quality Management
Avantor® to Host Third Quarter 2024 Earnings Call on Friday, October 25, 2024
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Avantor® Participates in BioProcess International 2024 Conference Scientific Program and Exhibition
Source: https://incomestatements.info
Category: Stock Reports